2018-02-13 (10 Days Old)Total Views: 20 | Last 7 Days: 1
TEL AVIV, Feb 13 (Reuters) - Israel-based Teva Pharmaceutical Industries said on Tuesday it had anticipated and planned for a second generic competitor to its multiple sclerosis treatment Copaxone to enter the market in 2018.
Daily Mail: Video: Arsene Wenger on Manchester City game in Carabao cup final
Daily Mail: Video: Dancer overcomes crippling scoliosis to pursue her passion
Daily Mail: Video: Giant blaze destroys 3-story apartment building in California
Daily Mail: Ballroom champ dances again after scoliosis surgery
Daily Mail: At least 18 killed after twin blasts and gunfire in...
Daily Mail: What is RHOBH star Kyle Richards’s net worth?
Daily Mail: Road closed after car and lorry crash
Daily Mail: Alex Jones and Maya Jama spotted at the BBC
CTV News: Funeral arrangements made for Howard McCurdy
CTV News: Tour bus driver fined for fatal crash in Banff National Park
CNBC: Instacart discovers a bug that withheld tips from shoppers and overcharged users
BBC: Bullish Trump jokes about hiding his bald spot
ABC: Japanese students voted to select official mascots for Tokyo 2020 Olympic Games
AP: Trump says son-in-law's clearance is up to Kelly
Daily Mail: US STOCKS-Stocks climb as Fed eases rate concern, tech...
Daily Mail: U.S. to move to 'phase 2' if N.Korea sanctions don't...
Daily Mail: Trump: chief of staff Kelly to decide on Kushner...
Daily Mail: 300 residents and 45 apartment units are destroyed in fire
FOX: Father who sparked fire that killed son gets prison
FOX: The Latest: Spokesman off staff list after profane tweet
FOX: Last teen pleads guilty in death of passenger hit by sandbag
ABC: Former Trump aide Rick Gates formally pleads guilty to two counts
Reuters: EU's Tusk warns Poland must stop anti-Semitic remarks